262 related articles for article (PubMed ID: 26194809)
1. Effects of neutropenia and histological responses in esophageal squamous cell carcinoma with neo-adjuvant chemotherapy.
Konishi H; Fujiwara H; Shiozaki A; Hiramoto H; Kosuga T; Komatsu S; Ichikawa D; Okamoto K; Otsuji E
Int J Clin Oncol; 2016 Feb; 21(1):95-101. PubMed ID: 26194809
[TBL] [Abstract][Full Text] [Related]
2. Comparison of neoadjuvant chemotherapy versus upfront surgery with or without chemotherapy for patients with clinical stage III esophageal squamous cell carcinoma.
Matsuda S; Tsubosa Y; Sato H; Takebayashi K; Kawamorita K; Mori K; Niihara M; Tsushima T; Yokota T; Onozawa Y; Yasui H; Takeuchi H; Kitagawa Y
Dis Esophagus; 2017 Feb; 30(2):1-8. PubMed ID: 26919154
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of pathological tumor response and residual nodal metastasis in patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Oguma J; Ozawa S; Koyanagi K; Kazuno A; Yamamoto M; Ninomiya Y; Yatabe K
Esophagus; 2019 Oct; 16(4):395-401. PubMed ID: 31190104
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the 7th edition of the TNM classification in patients with resected esophageal squamous cell carcinoma.
Wang J; Wu N; Zheng QF; Yan S; Lv C; Li SL; Yang Y
World J Gastroenterol; 2014 Dec; 20(48):18397-403. PubMed ID: 25561808
[TBL] [Abstract][Full Text] [Related]
5. Multimodality Treatment and Prognosis in Esophageal Squamous Cell Carcinoma Requiring Esophagectomy.
Yamashita K; Katada N; Moriya H; Hosoda K; Sakuramoto S; Kikuchi S; Watanabe M
Hepatogastroenterology; 2014 Jun; 61(132):1042-8. PubMed ID: 26158163
[TBL] [Abstract][Full Text] [Related]
6. The Presence of Serum p53 Antibody Predicts the Pathological Tumor Response to Neoadjuvant Chemotherapy with Docetaxel, Cisplatin and Fluorouracil (DCF) in Esophageal Squamous Cell Carcinoma.
Hiyoshi Y; Yoshida N; Watanabe M; Kurashige J; Baba Y; Sakamoto Y; Baba H
World J Surg; 2017 Feb; 41(2):480-486. PubMed ID: 27637603
[TBL] [Abstract][Full Text] [Related]
7. Clinical Significance of the Pre-therapeutic Nodal Size in Patients Undergoing Neo-Adjuvant Treatment Followed by Esophagectomy for Esophageal Squamous Cell Carcinoma.
Mine S; Watanabe M; Imamura Y; Okamura A; Kurogochi T; Sano T
World J Surg; 2017 Jan; 41(1):184-190. PubMed ID: 27468743
[TBL] [Abstract][Full Text] [Related]
8. Expression status of CD44 and CD133 as a prognostic marker in esophageal squamous cell carcinoma treated with neoadjuvant chemotherapy followed by radical esophagectomy.
Okamoto K; Ninomiya I; Ohbatake Y; Hirose A; Tsukada T; Nakanuma S; Sakai S; Kinoshita J; Makino I; Nakamura K; Hayashi H; Oyama K; Inokuchi M; Nakagawara H; Miyashita T; Hidehiro T; Takamura H; Fushida S; Ohta T
Oncol Rep; 2016 Dec; 36(6):3333-3342. PubMed ID: 27748881
[TBL] [Abstract][Full Text] [Related]
9. Safety and efficacy of preoperative chemotherapy followed by esophagectomy versus upfront surgery for resectable esophageal squamous cell carcinoma.
Kurogochi T; Honda M; Yamashita K; Hayami M; Okamura A; Imamura Y; Mine S; Watanabe M
Surg Today; 2019 Feb; 49(2):150-157. PubMed ID: 30276466
[TBL] [Abstract][Full Text] [Related]
10. Neoadjuvant chemotherapy with irinotecan and nedaplatin in a single cycle followed by esophagectomy on cT4 resectable esophageal squamous cell carcinoma: a prospective nonrandomized trial for short-term outcomes.
Tian D; Zhang L; Wang Y; Chen L; Zhang KP; Zhou Y; Wen HY; Fu MY
Dis Esophagus; 2019 Mar; 32(3):. PubMed ID: 30247659
[TBL] [Abstract][Full Text] [Related]
11. The prognostic significance of the positive circumferential resection margin in pathologic T3 squamous cell carcinoma of the esophagus with or without neoadjuvant chemotherapy.
Okada N; Fujii S; Fujita T; Kanamori J; Kojima T; Hayashi R; Daiko H
Surgery; 2016 Feb; 159(2):441-50. PubMed ID: 26391150
[TBL] [Abstract][Full Text] [Related]
12. Prognostic significance of tumor regression grade for patients with esophageal squamous cell carcinoma after neoadjuvant chemotherapy followed by surgery.
Hatogai K; Fujii S; Kojima T; Daiko H; Kadota T; Fujita T; Yoshino T; Doi T; Takiguchi Y; Ohtsu A
J Surg Oncol; 2016 Mar; 113(4):390-6. PubMed ID: 27100024
[TBL] [Abstract][Full Text] [Related]
13. Adjuvant chemotherapy after esophagectomy: is there a role in the treatment of the lymph node positive thoracic esophageal squamous cell carcinoma?
Lyu X; Huang J; Mao Y; Liu Y; Feng Q; Shao K; Gao S; Jiang Y; Wang J; He J
J Surg Oncol; 2014 Dec; 110(7):864-8. PubMed ID: 24976079
[TBL] [Abstract][Full Text] [Related]
14. Risk factors of early recurrence within 6 months after esophagectomy following neoadjuvant chemotherapy for resectable advanced esophageal squamous cell carcinoma.
Yoshida N; Baba Y; Shigaki H; Harada K; Iwatsuki M; Sakamoto Y; Miyamoto Y; Kurashige J; Kosumi K; Tokunaga R; Watanabe M; Baba H
Int J Clin Oncol; 2016 Dec; 21(6):1071-1078. PubMed ID: 27255393
[TBL] [Abstract][Full Text] [Related]
15. Prognostic histological factors in patients with esophageal squamous cell carcinoma after preoperative chemoradiation followed by surgery.
Tu CC; Hsu PK; Chien LI; Liu WC; Huang CS; Hsieh CC; Hsu HS; Wu YC
BMC Cancer; 2017 Jan; 17(1):62. PubMed ID: 28103913
[TBL] [Abstract][Full Text] [Related]
16. Effects of Neoadjuvant Chemoradiotherapy on Pathological TNM Stage and Their Prognostic Significance for Surgically-treated Esophageal Squamous Cell Carcinoma.
Hamai Y; Hihara J; Emi M; Furukawa T; Ibuki Y; Yamakita I; Kurokawa T; Okada M
Anticancer Res; 2017 Oct; 37(10):5639-5646. PubMed ID: 28982881
[TBL] [Abstract][Full Text] [Related]
17. Neoadjuvant versus adjuvant chemoradiation for stage II-III esophageal squamous cell carcinoma: a single institution experience.
Chen Y; Hao D; Wu X; Xing W; Yang Y; He C; Wang W; Liu J; Wang J
Dis Esophagus; 2017 Jul; 30(7):1-7. PubMed ID: 28475725
[TBL] [Abstract][Full Text] [Related]
18. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.
Duan J; Deng T; Ying G; Huang D; Zhang H; Zhou L; Bai M; Li H; Yang H; Qu Y; Wang X; Ba Y
Jpn J Clin Oncol; 2016 Apr; 46(4):336-43. PubMed ID: 26819278
[TBL] [Abstract][Full Text] [Related]
19. C-reactive protein to albumin ratio is a prognostic factor for patients with cStage II/III esophageal squamous cell cancer.
Otowa Y; Nakamura T; Yamamoto M; Kanaji S; Matsuda Y; Matsuda T; Oshikiri T; Sumi Y; Suzuki S; Kakeji Y
Dis Esophagus; 2017 Dec; 30(12):1-5. PubMed ID: 28881893
[TBL] [Abstract][Full Text] [Related]
20. Changes in modified Glasgow prognostic score after neoadjuvant chemotherapy is a prognostic factor in clinical stage II/III esophageal cancer.
Otowa Y; Nakamura T; Takiguchi G; Tomono A; Yamamoto M; Kanaji S; Imanishi T; Suzuki S; Tanaka K; Itoh T; Kakeji Y
Dis Esophagus; 2016; 29(2):146-51. PubMed ID: 25515972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
